Craig D. Seaman
Expertise in
14
conditions

Dr. Craig D. Seaman

Hematology
3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
14
conditions
3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 

Overview

Craig Seaman is a Hematologist practicing medicine in Pittsburgh, Pennsylvania.

Dr. Seaman is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Von Willebrand Disease (VWD), Hemophilia A, Blood Clots, and Hemophilic Arthropathy.

Dr. Seaman is board certified in American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 5 clinical trials. Dr. Seaman is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in PA

Board Certifications

American Board Of Internal Medicine

Fellowships

University of Pittsburgh School of Medicine

Hospital Affiliations

Upmc Presbyterian Shadyside

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Classical Hematology
3601 Fifth Ave, Falk Building, 3rd Floor, Pittsburgh, PA 15213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Prospective, Randomized, Crossover Trial Comparing Recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to Minimize Menorrhagia in Women With Von Willebrand Disease: The VWD Minimize Study
Enrollment Status: Terminated
Publish Date: July 01, 2024
Intervention Type: Drug
Study Drugs: Von Willebrand Factor, Tranexamic Acid
Study Phase: Phase 3
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: April 11, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Phase III Multi-Center, Randomized, Controlled Inhibitor Eradication Trial, Comparing Eloctate Immune Tolerance Induction (ITI) Plus Emicizumab vs. Eloctate ITI Alone to Eradicate Inhibitor Formation in Severe Hemophilia A
Enrollment Status: Terminated
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drugs: Eloctate ITI, Emicizumab
Study Phase: Phase 3
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
A Longitudinal, Observational Study of Previously Treated Hemophilia Patients Switching Factor Replacement Products
Enrollment Status: Completed
Publish Date: December 09, 2021
Intervention Type: Biological
Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
Phase III INHIBIT Platform: Prevention Trial, Eloctate vs Emicizumab to Prevent Inhibitors; Eradication Trial: Eloctate Immune Tolerance (ITI) Plus Emicizumab vs vs Eloctate ITI Alone to Eradicate Inhibitors in Severe Hemophilia A
Enrollment Status: Withdrawn
Publish Date: August 20, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

27 Total Publications

Risk of Postpartum Hemorrhage in Women With Von Willebrand Disease: A Real-World Data Analysis.
Risk of Postpartum Hemorrhage in Women With Von Willebrand Disease: A Real-World Data Analysis.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 18, 2026
Similar Doctors
Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required
Before you request

Classical Hematology

3601 Fifth Ave, Falk Building, 3rd Floor, 
Pittsburgh, PA 
 (0.1 miles away)
412-586-9875
Languages Spoken:
English, Italian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Enrico M. Novelli, MD, is a classical (benign) hematologist, the Chief of the Section of Benign Hematology, and the medical director of the UPMC Adult Sickle Cell Disease Program. Board-certified in hematology, Dr. Novelli received his medical degree from the University of Milan, Italy. He completed his residency in internal medicine and fellowship in hematology-oncology at UPMC. Dr. Novelli specializes in sickle cell anemia and hemoglobinopathies. Dr. Novelli is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy. Dr. Novelli is board certified in American Board Of Internal Medicine. Dr. Novelli is currently accepting new patients.

Expertise in
38
conditions
Expertise in
38
conditions
Referral may be required

Univ. Of Pittsburgh Cancer Institute Cancer Services

5115 Centre Ave Fl 3, 
Pittsburgh, PA 
 (1.4 miles away)
412-235-1020
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mounzer Agha is a Hematologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Agha is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Agha is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

Mario Lemieux Center For Blood Cancers

5115 Centre Ave Fl 4, 
Pittsburgh, PA 
 (1.4 miles away)
412-864-6600
Languages Spoken:
English
See accepted insurances

Anastasios Raptis is a Hematologist practicing medicine in Pittsburgh, Pennsylvania. Dr. Raptis is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Craig D. Seaman

How do I make an appointment with Dr. Craig D. Seaman?

You can book an appointment with Dr. Craig D. Seaman by calling their office at 412-586-9875. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Craig D. Seaman a top-rated expert for Von Willebrand Disease (VWD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Craig D. Seaman is classified as an Elite expert for Von Willebrand Disease (VWD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Craig D. Seaman specialize in?

While Dr. Craig D. Seaman is a Hematology, they have specific expertise in Von Willebrand Disease (VWD), Hemophilia A, and Blood Clots. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Craig D. Seaman participate in research or clinical trials?

Yes. Dr. Craig D. Seaman has published 27 articles and abstracts on conditions like Von Willebrand Disease (VWD). You can view a list of Dr. Craig D. Seaman's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Craig D. Seaman accept my insurance?

Dr. Craig D. Seaman accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 412-586-9875 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Seaman's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 17 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile